Back to Search
Start Over
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
- Source :
-
Future oncology (London, England) [Future Oncol] 2021 Nov; Vol. 17 (32), pp. 4237-4247. Date of Electronic Publication: 2021 Aug 23. - Publication Year :
- 2021
-
Abstract
- Crizotinib is highly efficacious and more tolerable than chemotherapy for ALK <superscript>+</superscript>  non-small-cell lung cancer (NSCLC), but its progression-free survival benefit and intracranial efficacy have limitations. Head-to-head comparisons of next-generation ALK inhibitors in patients with ALK <superscript>+</superscript> NSCLC progressing on crizotinib will contribute toward optimizing survival. This international, Phase III, randomized, open-label study (ALTA-3) will therefore assign patients with locally advanced or metastatic ALK <superscript>+</superscript> NSCLC progressing on crizotinib to receive either brigatinib 180 mg qd (7-day lead-in at 90 mg qd) or alectinib 600 mg twice daily. The primary end point is progression-free survival as assessed by a blinded Independent Review Committee; the key secondary end point is overall survival. Clinical trial registration number: NCT03596866 (ClinicalTrials.gov).
- Subjects :
- Anaplastic Lymphoma Kinase antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung mortality
Drug Resistance, Neoplasm
Female
Humans
Lung Neoplasms mortality
Male
Anaplastic Lymphoma Kinase analysis
Carbazoles therapeutic use
Carcinoma, Non-Small-Cell Lung drug therapy
Crizotinib therapeutic use
Lung Neoplasms drug therapy
Organophosphorus Compounds therapeutic use
Piperidines therapeutic use
Pyrimidines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8301
- Volume :
- 17
- Issue :
- 32
- Database :
- MEDLINE
- Journal :
- Future oncology (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 34423676
- Full Text :
- https://doi.org/10.2217/fon-2021-0608